CACO Workshop, Friday, Sept. 16, 2011
Topic: “QT prolongation and Thorough QT study for cardiac safety – What a drug developer should know”
Speaker: Peter Staehr, MD, Senior Director, Cardiovascular/Metabolic Therapeutic Area, Gilead Sciences, Inc., Palo Alto
Date and Time: Friday, Sept. 16, 2011, 11:00-13:30
Location: Foster City Crowne Plaza
Speaker Bio
Dr. Peter Staehr in his current role as head of Clinical Pharmacology and Research along with his team designs full-fledged clinical drug development programs for New Chemical Entities and conducts Phase 1-4 clinical studies in the cardiometabolic therapeutic area of GILEAD Sciences Inc. Under his leadership the team transitioned a novel adenosine agonist for the treatment of type 2 diabetes and dyslipidemia into the clinic, where currently it is in Phase 2.
Prior to joining Gilead Sciences Inc, Dr. Staehr had appointments in demanding leadership roles at Johnson&Johnson/Alza and CV Therapeutics. He has a track record of successful Regulatory submissions and drug approvals by both the FDA (Lexiscan
